Intech Investment Management LLC Decreases Stock Position in Medtronic PLC $MDT

Intech Investment Management LLC trimmed its holdings in shares of Medtronic PLC (NYSE:MDT) by 41.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 75,386 shares of the medical technology company’s stock after selling 53,102 shares during the period. Intech Investment Management LLC’s holdings in Medtronic were worth $7,180,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Delos Wealth Advisors LLC bought a new position in shares of Medtronic during the second quarter valued at $27,000. Corundum Trust Company INC bought a new stake in Medtronic in the 3rd quarter worth about $27,000. Valley Wealth Managers Inc. purchased a new position in Medtronic in the 3rd quarter worth about $29,000. Steigerwald Gordon & Koch Inc. purchased a new position in Medtronic in the 3rd quarter worth about $33,000. Finally, Tripletail Wealth Management LLC bought a new position in Medtronic during the 3rd quarter valued at about $34,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 0.6%

Shares of Medtronic stock opened at $97.60 on Friday. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The company’s fifty day simple moving average is $98.93 and its 200-day simple moving average is $96.86. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.80. The stock has a market capitalization of $125.31 billion, a PE ratio of 27.19, a P/E/G ratio of 2.44 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on MDT. Leerink Partners reduced their price target on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating for the company in a research note on Wednesday, February 18th. Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Wells Fargo & Company assumed coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “overweight” rating and a $114.00 target price for the company. Finally, Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.84.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).